Ireland
--:--IST
Recruiting Not applicable

A Study to Characterize Human Skin Changes From Biostimulator Treatments Via Non-invasive Imaging

NCT07399028 · tracked via the Priya Life Science USA tracker
Phase
Not applicable
Started
2025-10-21
Last updated
2026-02-10

Condition(s) studied

Volume Deficiency in the Mid-FaceSkin LaxityPhoto-aged Skin

Investigational drug(s) / intervention(s)

Sculptra®

Sculptra®: Sculptra injection will be performed to the cheeks using 25 G needle size. Injections will be performed subdermally, i.e., in the subcutaneous and supraperiosteal region. A maximum of 18 mL (2 vials) of Sculptra will be administered per treatment session with a maximum of 9 mL (1 vial) per cheek, evenly distributed within the treatment area.

Study summary

Adult subjects with moderate-to-severe cheek wrinkles will be treated with Sculptra for correction of fine lines and wrinkles in the cheek area.

Eligibility

Sex
FEMALE
Min age
45 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Adult subjects aged 45-65 years old * Females only * Subject with moderate-to-severe cheek wrinkles on the GCWS * Subject with intent to undergo correction of cheek wrinkles on both sides of the face * Subject who in the opinion of the Investigator would need 3 treatments for optimal clinical outcomes * Subject willing to be photographed at each visit. * Subjects willing to stop using current facial skincare products for the duration of the study. * Subject willing to replace the current facial skincare products with the provided facial skincare products, including cleanser, moisturizer and sunscreen, until study completion. * Ability to read, understand and give consent for participation in the study. * Agreement to adhere to the procedures and requirements of the study and to report to the site on the day(s) and at the time(s) scheduled for the assessments. Exclusion Criteria: * Subjects with a history of allergy or hypersensitivity to any ingredient of the treatment products. * Previous tissue-augmenting therapy, contouring, or revitalization treatment in the face, except lips. * Previous treatment/procedure in the face in the previous 6 months that, in the Investigator's opinion, would interfere with the study injections and/or study assessments or exposed the study subject to undue risk by study participation, or planning to undergo any of these procedures affecting the treatment area at any time during the study. * Subjects with any medical condition that, in the opinion of the Investigator, would make the subject unsuitable for inclusion.

Primary outcome measure(s)

  • Structural change in midface post-treatment with a biostimulator compared to pre-treatment assessed by standardized VISIA imaging and optical biopsy imaging — 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 20 weeks after baseline
    Images taken with VISIA imaging system and an imaging system using tomography technology at baseline and post-baseline timepoints will be compared to assess structural changes in cheeks.

Trial sites (1)

FacilityCityRegionStatus
Luxurgery New York New York Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07399028 on ClinicalTrials.gov ↗ ← All trials in the USA